The deepening global financial crisis is forcing a bitter pill down the throat of Indian drug makers with companies pruning their ambitious R&D plans. "If an industry's viewpoint is taken some changes will be there. The R&D spending will go down to 6-8 per cent from 10 per cent," said Dr CB Rao, deputy MD, Orchid Chemicals.
